Pyxis Oncology's EBIT per Share for the
three
months ended in Mar. 2024 was $-0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.59.
During the past 3 years, the average EBIT per Share Growth Rate was -52.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pyxis Oncology's EBIT per Share or its related term are showing as below:
PYXS'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -205.6 Med: -128.95 Max: -52.3
Current: -52.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Pyxis Oncology was -52.30% per year. The lowest was -205.60% per year. And the median was -128.95% per year.
PYXS's 3-Year EBIT Growth Rate is ranked worse than 90.11% of 1305
companies
in the Biotechnology industry
Industry Median: 3.4
vs PYXS: -52.30
Pyxis Oncology's EBIT for the
three
months ended in Mar. 2024 was $-5.61 Mil.
Pyxis Oncology EBIT per Share Historical Data
The historical data trend for Pyxis Oncology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (NAS:PYXS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pyxis Oncology EBIT per Share Related Terms
Thank you for viewing the detailed overview of Pyxis Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Pyxis Oncology (Pyxis Oncology) Business Description
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PYXS has been successfully added to your 